These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12042205)

  • 41. Dose-dependent increase in the QTc interval in aripiprazole treatment after risperidone.
    Suzuki Y; Ono S; Fukui N; Sugai T; Watanabe J; Tsuneyama N; Someya T
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):643-4. PubMed ID: 21044656
    [No Abstract]   [Full Text] [Related]  

  • 42. Psychiatric medications and sudden cardiac death: putting the risk in perspective.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Feb; 53(2):23-5. PubMed ID: 25654571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval.
    Schmidt A; Fischer P; Wally B; Scharfetter J
    Neuropsychiatr; 2017 Dec; 31(4):172-175. PubMed ID: 28791627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study.
    Blair J; Scahill L; State M; Martin A
    J Am Acad Child Adolesc Psychiatry; 2005 Jan; 44(1):73-9. PubMed ID: 15608546
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose haloperidol-associated QTc prolongation.
    Stepkovitch K; Heagle Bahn C; Gupta R
    J Am Geriatr Soc; 2008 Oct; 56(10):1963-4. PubMed ID: 19054204
    [No Abstract]   [Full Text] [Related]  

  • 46. Free your MIND and the rest will follow: decoding delirium in the intensive care unit.
    Balas MC
    Crit Care Med; 2010 Feb; 38(2):697-8. PubMed ID: 20083930
    [No Abstract]   [Full Text] [Related]  

  • 47. Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report.
    Létourneau G; Abdel-Baki A; Dubreucq S; Mahone M; Granger B
    J Clin Psychopharmacol; 2011 Oct; 31(5):671-3. PubMed ID: 21881458
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
    Glassman AH
    J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
    Mencacci C;
    Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Re: Thioridazine: re-evaluating the risk/benefit equation.
    Timell AM
    Ann Clin Psychiatry; 2003 Jun; 15(2):131. PubMed ID: 12938870
    [No Abstract]   [Full Text] [Related]  

  • 52. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia.
    Ozeki Y; Fujii K; Kurimoto N; Yamada N; Okawa M; Aoki T; Takahashi J; Ishida N; Horie M; Kunugi H
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):401-5. PubMed ID: 20079791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Atypical antipsychotic drugs and the risk of sudden cardiac death.
    Price LH
    N Engl J Med; 2009 May; 360(20):2137; author reply 2137-8. PubMed ID: 19445034
    [No Abstract]   [Full Text] [Related]  

  • 54. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
    Scahill L; Blair J; Leckman JF; Martin A
    J Psychopharmacol; 2005 Mar; 19(2):205-6. PubMed ID: 15728441
    [No Abstract]   [Full Text] [Related]  

  • 55. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature.
    Katagai H; Yasui-Furukori N; Kikuchi A; Kaneko S
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):568-70. PubMed ID: 17875038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aripiprazole-associated QTc prolongation in a geriatric patient.
    Hategan A; Bourgeois JA
    J Clin Psychopharmacol; 2014 Dec; 34(6):766-8. PubMed ID: 25203469
    [No Abstract]   [Full Text] [Related]  

  • 59. QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.
    LLerena A; Berecz R; de la Rubia A; Dorado P
    Eur J Clin Pharmacol; 2002 Jun; 58(3):223-24. PubMed ID: 12162273
    [No Abstract]   [Full Text] [Related]  

  • 60. Ziprasidone for sedation of the agitated ED patient.
    Martel ML
    Am J Emerg Med; 2004 May; 22(3):238. PubMed ID: 15138973
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.